Genmab A/S

Genmab A/S FCF/Debt

The Free Cash Flow to Debt Ratio of Genmab A/S (GMAB.CO) as of Oct 1, 2026 is 21.49 %. In the previous year, Free Cash Flow to Debt Ratio was 737.03 % — a change of -97.08% (lower).

FCF/Debt

21.49 %

YoY

-97.08%

Last updated:

Free Cash Flow to Debt Ratio of Genmab A/S is 2026 21.49 % . Free Cash Flow to Debt Ratio of Genmab A/S was 2025 737.03 % . It decreases by -97.08% lower compared to the previous year.

The Genmab A/S FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2016
478.17 USD
Jan 1, 2019
671.27 USD
Jan 1, 2020
1,920.38 USD
Jan 1, 2021
464.94 USD
Jan 1, 2022
602.18 USD
Jan 1, 2023
909.61 USD
Jan 1, 2024
737.03 USD
Jan 1, 2025
21.49 USD
The Genmab A/S FCF/Debt history
YEARFCF/DebtYoY
21.49 %-97.08%
737.03 %-18.97%
909.61 %+51.05%
602.18 %+29.52%
464.94 %-75.79%
1,920.38 %+186.08%
671.27 %+40.38%
478.17 %-99.68%
149,203.40 %+825.53%
16,120.85 %—
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Free Cash Flow to Debt Ratio of Genmab A/S is 21.49 % in 2026.

Free Cash Flow to Debt Ratio of Genmab A/S changed from 737.03 % to 21.49 %, representing a -97.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Genmab A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Genmab A/S

All Key Metrics — Genmab A/S